Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Studies in humans and mice have shown that increased expression of apolipoprotein C-I (apoC-I) results in combined hyperlipidemia with a more pronounced effect on triglycerides (TGs) compared with total cholesterol (TC). The aim of this study was to elucidate the main reason for this effect using human apoC-I-expressing (APOC1) mice. Moderate plasma human apoC-I levels (i.e., 4-fold higher than human levels) caused a 12-fold increase in TG, along with a 2-fold increase in TC, mainly confined to VLDL. Cross-breeding of APOC1 mice on an apoE-deficient background resulted in a marked 55-fold increase in TG, confirming that the apoC-I-induced hyperlipidemia cannot merely be attributed to blockade of apoE-recognizing hepatic lipoprotein receptors. The plasma half-life of [3H]TG-VLDL-mimicking particles was 2-fold increased in APOC1 mice, suggesting that apoC-I reduces the lipolytic conversion of VLDL. Although total postheparin plasma LPL activity was not lower in APOC1 mice compared with controls, apoC-I was able to dose-dependently inhibit the LPL-mediated lipolysis of [3H]TG-VLDL-mimicking particles in vitro with a 60% efficiency compared with the main endogenous LPL inhibitor apoC-III. Finally, purified apoC-I impaired the clearance of [3H]TG-VLDL-mimicking particles independent of apoE-mediated hepatic uptake in lactoferrin-treated mice. Therefore, we conclude that apoC-I is a potent inhibitor of LPL-mediated TG-lipolysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751
Plump, A. S., Smith, J. D., Hayek, T., Aalto-Setälä, K., Walsh, A., Verstuyft, J. G., Rubin, E. M., & Breslow, J. L. (1992) · Cell · doi:10.1016/0092-8674(92)90362-g · Cited by 2,263
Hypertriglyceridemia as a Result of Human apo CII Gene Expression in Transgenic Mice
Ito, Y., Azrolan, N., O'Connell, A., Walsh, A., & Breslow, J. L. (1990) · Science · doi:10.1126/science.2167514 · Cited by 539
Kowal, R. C., Herz, J., Weisgraber, K. H., Mahley, R. W., Brown, M. S., & Goldstein, J. L. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)87014-4 · Cited by 445 · cited 6×
“, LDLr and LRP) (22, 23, 46), although Quarfordt, Michalopoulos, and Schirmer (21) reported that”
BackgroundInfluentialRensen, P. C. N., & van Berkel, T. J. C. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.25.14791 · Cited by 144 · cited 3×
“ment with our previous observations (36, 37).”
BackgroundMethodSelf-citationProtection From Obesity in Mice Lacking the VLDL Receptor
Goudriaan, J. R., Tacken, P. J., Dahlmans, V. E. H., Gijbels, M. J. J., van Dijk, K. W., Havekes, L. M., & Jong, M. C. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq0901.095147 · Cited by 133
Self-citationVery Low Density Lipoprotein (VLDL) Receptor-deficient Mice Have Reduced Lipoprotein Lipase Activity
Yagyu, H., Lutz, E. P., Kako, Y., Marks, S., Hu, Y., Choi, S. Y., Bensadoun, A., & Goldberg, I. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109966200 · Cited by 123
Mezdour, H., Jones, R., Dengremont, C., Castro, G., & Maeda, N. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.21.13570 · Cited by 113 · cited 1×
“However, although these studies certainly suggest a modulating role of apoC-I with respect to hepatic lipoprotein recognition, it remains remarkable that complete blockade of the apoE-mediated lipoprotein clearance in apoE-deficient mice hardly affects plasma TG levels (16, 25, 26), whereas TG levels are severely incr…”
BackgroundObunike, J. C., Lutz, E. P., Li, Z., Paka, L., Katopodis, T., Strickland, D. K., Kozarsky, K. F., Pillarisetti, S., & Goldberg, I. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008813200 · Cited by 91 · cited 6×
“Since a variety of effects on lipid metabolism has been attributed to apoCI, including activatory effects (e.g. LCAT) and inhibitory effects (e.g. HL, CETP, intestinal absorption, and apoE-dependent recognition by LRP, LDLr and VLDLr), the aim of the present study was to elucidate the main mechanism underlying the apo…”
BackgroundInfluentialApolipoprotein E Is Resistant to Intracellular Degradation in Vitro and in Vivo
Rensen, P. C. N., Jong, M. C., van Vark, L. C., van der Boom, H., Hendriks, W. L., van Berkel, T. J. C., Biessen, E. A. L., & Havekes, L. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.8564 · Cited by 86 · cited 1×
“To investigate whether an impaired lipolytic processing of TG-rich lipoproteins may contribute to the hypertriglyceridemia observed in APOC1 mice, mice were injected with [3H]TO-labeled protein-free VLDL-like emulsion particles, which have previously been shown to mimic the metabolic behavior of TG-rich lipoproteins (…”
MethodSelf-citation
Cited by
Physiological regulation of lipoprotein lipase
Kersten, S. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.03.013 · Cited by 550
Mandard, S., Zandbergen, F., van Straten, E., Wahli, W., Kuipers, F., Müller, M., & Kersten, S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m506519200 · Cited by 433
Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease
Rosenson, R. S., Davidson, M. H., Hirsh, B. J., Kathiresan, S., & Gaudet, D. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.042 · Cited by 260
Helgadottir, A., Gretarsdottir, S., Thorleifsson, G., Hjartarson, E., Sigurdsson, A., Magnusdottir, A., Jonasdottir, A., Kristjansson, H., Sulem, P., Oddsson, A., et al. (2016) · Nature Genetics · doi:10.1038/ng.3561 · Cited by 254
Wolska, A., Dunbar, R. L., Freeman, L. A., Ueda, M., Amar, M. J., Sviridov, D. O., & Remaley, A. T. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.10.025 · Cited by 231
Metadata
- Authors
- Berbée, J. F. P., van der Hoogt, C. C., Sundararaman, D., Havekes, L. M., & Rensen, P. C. N.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2005-02
- Volume
- 46
- Issue
- 2
- Pages
- 297-306
- ISSN
- 0022-2275 (ISSN-L)
- OpenAlex
- W1983089921
- Cited by
- 137
- References
- 10
- FWCI
- 4.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL. https://app.cochat.ai/papers/10.1194/jlr.m400301-jlr200
- The paper
- Berbée, J. F. P., van der Hoogt, C. C., Sundararaman, D., Havekes, L. M., & Rensen, P. C. N. (2005). Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL. Journal of Lipid Research. https://doi.org/10.1194/jlr.m400301-jlr200
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.